- June 10, 2019
- Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Forms Japan-based Corporate Venture Capital Firm to Foster Healthcare Startups in Japan
Taiho Pharmaceutical Co., Ltd. today announced the establishment of Taiho Innovations, LLC, a strategic corporate venture capital firm in Tokyo, Japan, to invest in healthcare startups in Japan.
Taiho Innovations will be supporting incubation and business growth in startup companies in Japan who have cutting-edge and innovative therapeutic products and/or drug discovery platform that demonstrate a clear potential benefit to patients. The company will also promote outbound open innovation with the aim of making external use of assets in its in-house research pipeline. Taiho Innovations will make investments one billion yen in the first several years.
Taiho Innovations is the Taiho Pharmaceutical’s second corporate venture capital firm following Taiho Ventures, LLC which was established in 2016 in the US. While Taiho Ventures invests in biotech startups mainly in the US and EU focusing on the field of oncology, Taiho Innovations will make investments in healthcare startups in the field of therapeutics and consumer healthcare in Japan. In addition, Taiho Innovations will strive to create a novel healthcare business through cross-industry collaboration and joint venture creation.
Taiho Pharmaceutical pursues initiatives to spur and leverage innovations continuously to keep creating new businesses globally. The company will enhance its drug discovery capabilities through corporate venture investments and their networks. Taiho Pharmaceutical will continue to contribute in building a sustainable society by promoting innovations in Japan.
Taiho Innovations Overview
|Company Name||Taiho Innovations, LLC|
|Location||Chiyoda-ku, Tokyo, Japan|
|Business||Venture capital and incubation|
|Investment size||1 billion yen|
|Investment sectors:||Therapeutics (including oncology and rare diseases)
New healthcare fields
|Geographical area of investment||Japan|
Information in this news release was current as of the original release date.